comparemela.com

Latest Breaking News On - Prnewswire inhibrx inc - Page 1 : comparemela.com

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Ukraine
Brendan-eckelman
Prnewswire-inhibrx-inc
Exchange-commission
Inhibrx-inc
Securities-exchange
Company-annual-report-on-form
Nasdaq
Inhibrx-biosciences-inc
Company-on
Party-transactions
Company-definitive-proxy-statement

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Ukraine
Brendan-eckelman
Company-annual-report-on-form
Securities-exchange
Nasdaq
Exchange-commission
Prnewswire-inhibrx-inc
Inhibrx-inc
Company-definitive-proxy-statement
Party-transactions
Company-on
Inhibrx-biosciences-inc

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Ukraine
Brendan-eckelman
Prnewswire-inhibrx-inc
Company-on
Company-definitive-proxy-statement
Party-transactions
Company-annual-report-on-form
Exchange-commission
Securities-exchange
Inhibrx-inc
Inhibrx-biosciences-inc
Nasdaq

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101.

Ukraine
Pennsylvania
United-states
Kayyem-jon-faiz
Manhard-kimberly
Forsyth-douglas
Gotshal-manges
Inhibrx-biosciences-inc
Securities-exchange
Prnewswire-inhibrx-inc
Centerview-partners
Nasdaq

vimarsana © 2020. All Rights Reserved.